Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease.
Empatica is a full-stack digital health company and an MIT spin-off, with offices in Boston (MA), Milan (Italy), and Seoul (South Korea). We specialize in the development, production, and deployment of medical-grade wearables and digital biomarkers, powered by an AI-driven platform designed for continuous health monitoring and the early detection of medical conditions.
The FDA-cleared Empatica Health Monitoring Platform consists of the medical-grade EmbracePlus and EmbraceMini wearables and the world’s largest selection of validated digital measures, enabling thousands of institutional partners to remotely collect patient health data, in trials and studies on sleep, stress, epilepsy, and more.
Empatica’s Embrace wearable was the world’s first FDA-cleared smartwatch in neurology to detect epileptic seizures. In 2024, we launched its successor, EpiMonitor, with all of the most loved features of Embrace and even more. EpiMonitor is an all-in-one wearable and smartphone application solution for detecting possible generalized tonic-clonic seizures, alerting caregivers during emergencies, and monitoring epilepsy. It is the only FDA-cleared wrist-worn wearable and app combination for epilepsy monitoring in the US.